Behind the announcement of inflated pricing and withdrawal of funds by three subordinate companies: Baiyunshan's "troubled years"
Wu Yue, editor of "Investor Network" Jordan, has just passed the third quarter, which can be said to be an "eventful time" for 600332.SH. On the one hand, the company's three subordinate companies were informed by National Healthcare Security Administration of the existence of inflated pricing, the situation of taking funds. In the past spot checks conducted by the Guangzhou Market Regulatory Administration, the three companies also had situations in varying degrees, such as "problems have been found that they have been ordered to correct" and "problems have been found to be dealt with later." On the other hand, the company's star brand "Wang Laoji" was "cheated" by a dealer rights storm triggered by "false investment". Soon after that, Guang Yao Ji
National Health Commission: carry out TCM intervention activities in adolescent myopia, obesity and scoliosis
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Top Owners Are Private Companies With 48% Stake, While 35% Is Held by Individual Investors
If you want to know who really controls Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874), then you'll have to look at the makeup of its share registry. We can see that private c
Baiyunshan: interim report 2022
Could The Market Be Wrong About Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Given Its Attractive Financial Prospects?
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) has had a rough month with its share price down 10.0%. However, a closer look at its sound financials might cause you to think again. Given tha
Baiyunshan: summary of the semi-annual report 2022
Baiyunshan: the date of the board meeting
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 45% Below Their Intrinsic Value Estimate
Does the August share price for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by taking th
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) stock falls 6.7% in past week as three-year earnings and shareholder returns continue downward trend
Many investors define successful investing as beating the market average over the long term. But in any portfolio, there are likely to be some stocks that fall short of that benchmark. We regret to
Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will